Shots: Cue Biopharma will conduct a P-I KEYNOTE-A78 study assessing the combination therapy as 1L treatment for HPV+ advanced head and neck cancer. KEYNOTE-A78 will be conducted in parallel with […]readmore
Tags : Head and Neck Cancer
Shots: The BTD is based on P-II results that demonstrated improvement of the 1EPs locoregional control rate @18mos. after CRT (21% improvement vs. control arm) and a marked PFS benefit […]readmore
Shots: AstraZeneca will evaluate the combination of Monalizumab with Cetuximab for patients with recurrent or metastatic squamous cell carcinoma of the head and neck (SCCHN) with the anticipated onset of […]readmore